Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649272 | Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg | PHASE1 | COMPLETED | 80 | — | — | Jan 1, 2006 | Feb 1, 2006 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oxybutynin Chloride Extended-Release Tablets, 15 mg |
| 2 | ACTIVE_COMPARATOR | Ditropan XL® Extended-release tablets, 15 mg |
| Name | Type | Description |
|---|---|---|
| Oxybutynin Chloride Extended-Release Tablets, 15 mg | DRUG | 15mg, single dose fasting |
| Ditropan XL® Extended-release tablets, 15 mg | DRUG | 15mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to the start of the study and on the even...